MedTrace Logo

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

NCT02456740 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 955

Last updated 2022-10-12

Study results available
· View outcomes & findings →

Summary

The primary objective of the study was to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days.

Conditions

Interventions

DRUG

Erenumab

Administered by subcutaneous injection once a month

DRUG

Placebo

Administered by subcutaneous injection once a month

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-17
Primary Completion
2016-09-05
Completion
2017-06-19

Countries

  • United States
  • Austria
  • Belgium
  • Canada
  • Czechia
  • Finland
  • Germany
  • Netherlands
  • Poland
  • Slovakia
  • Sweden
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02456740 on ClinicalTrials.gov